HSBC Downgrades Amgen to Hold, Lowers Price Target to $425

Benzinga Newsdesk www.benzinga.com Negative 89.5%

Neg 89.5% Neu 0% Pos 0%

HSBC analyst Morten Herholdt downgrades Amgen (NASDAQ:AMGN) from Buy to Hold and lowers the price target from $445 to $425.